News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: honestabe13 post# 113346

Friday, 02/22/2013 10:15:49 PM

Friday, February 22, 2013 10:15:49 PM

Post# of 347009
I sure hope its not for anything to do with the ATM.

My extreme hopium addiction may be influencing my reaction but here is why I think its not for ATM:

1) IF for ATM just to raise money.... why the trip to NY and Boston on top of the conferences lined up in March (Cowen and Roth)and I would think if they need to raise money... it can easily be done from the office over the phone

2) Key clients (one or more or VC group) are interested but want to hear first hand the entire story from Peregrine in person.

NOTE: Whether BP talks are going well.... agreeing on terms or not... I think Peregrine will keep moving along in getting interest back in their corner. BP's may see this momentum swing and like the 4 year old who sees someone else holding something (shares)... it gets that BP "more" motivated to get a deal done on Peregrines terms.

To me it seems more like they are laying out their version to the ... big money clients.... and will give their future outlook... and offer hints on the news to come and give them the opportunity to invest in Peregrine now at these prices. This help raise the Institutional Ownership... and at the same time puts pressure on the partnering talks.... one will give in first and either one is going to help the stock price.

Peregrine is not going to NY and Boston on a bluff and nothing to show for it.... clients want to see their cards on the table

Peregrine is not going to go to a medical conference on a bluff... medical community will see all the cards on the table

As for the BP's.... I forgot who said it, but liked the part where it was mentioned that the partner will have their scientist maybe in one meeting .. if one... to verify this science is validated by data..etc and they will shuffle them back to the labs to hide the grins and smiles from their faces! ....as the lawyers M/A team walk back in for negotiations and try to low ball Peregrine in every way.

Peregrine can only make a partnering deal once and they don't want to be sitting at this years ASM regretting anything.

GLTA!




"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y